Skip to main content

Osmetech’s CYP450 2C9 Test, Fluidigm EP1 Genotyping System

Osmetech has launched a genetic test for CYP450 2C9 drug metabolism. The test identifies polymorphisms in the CYP2C9 gene, which the company said is associated with the metabolism of 10 percent of all drugs, including non-steroidal anti-inflammatory drugs, anticoagulants, anti-epileptic agents, cholesterol-lowering drugs, and anti-diabetic agents.
The CYP2C9 test is available for research use only on the company’s eSensor XT-8 System. The company said it “may also seek FDA approval” for the test.

Fluidigm this week launched its EP1 system for high-throughput SNP genotyping and digital PCR. The EP1 system offers integrated fluidic circuit-based genotyping in a desktop-sized configuration, the company said.
Fluidigm said that the EP1 system delivers “the highest quality SNP genotyping results on the market,” with call rates of 99 percent or more and 99.75 percent or greater accuracy.

The system provides more than 27,000 genotypes a day. Users can add IFC controllers and thermal cyclers to a single EP1 Reader in order to generate more than 200,000 genotypes per day, the company said.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.